High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 12, 2006, Pages 4182-4185

  Doualla Bell, Florence ^a,b   Avalos, Ava ^c   Brenner, Bluma ^b   Gaolathe, Tendani ^a,c   Mine, Madisa ^a   Gaseitsiwe, Simani ^a   Oliveira, Maureen ^b   Moisi, Daniella ^b   Ndwapi, Ndwapi ^a   Moffat, Howard ^c   Essex, Max ^a,d   Wainberg, Mark A ^b,e  

^a BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^b MCGILL UNIVERSITY   (Canada)

^c PRINCESS MARINA HOSPITAL   (Botswana)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ARTICLE; BOTSWANA; CLINICAL ARTICLE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS ISOLATION; VIRUS MUTATION;

ANTI-HIV AGENTS; BOTSWANA; DIDANOSINE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PREVALENCE;

EID: 33845242455     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00714-06     Document Type: Article

References (18)

1. Abecasis, A. B., K. Deforche, J. Snoeck, L. T. Bacheler, P. McKenna, A. P. Carvalho, P. Gomes, R. J. Camacho, and A. M. Vandamme. 2005. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 19:1799-1806.
2. Brenner, B., M. Oliveira, F. Doualla-Bell, D. Moisi, M. Ntemgwa, F. Frankel, M. Essex, and M. A. Wainberg. 2006. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 20:F9-F13.
3. Brenner, B., D. Turner, M. Oliveira, D. Moisi, M. Detorio, M. Carobene, R. G. Marlink, J. Schapiro, M. Roger, and M. A. Wainberg. 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17:F1-F5.
4. Chaix, M. L., D. Descamps, M. Harzic, V. Schneider, C. Deveau, C. Tamalet, I. Pellegrin, J. Izopet, A. Ruffault, B. Masquelier, L. Meyer, C. Rouzioux, F. Brun-Vezinet, and D. Costagliola. 2003. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS 17:2635-2643.
5. Doualla-Bell, F., S. Gaseitsiwe, T. Ndungu, M. Modukanele, T. Peter, V. A. Novitsky, N. Ndwapi, G. Tendani, A. Avalos, W. Wester, H. Bussmann, P. Cardiello, R. Marlink, H. Moffat, I. Thior, M. A. Wainberg, and M. Essex. 2004. Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. Antivir. Chem. Chemother. 15:189-200.
6. Doualla-Bell, F., A. Avalos, T. Gaolathe, M. Mine, S. Gaseitsiwe, N. Ndwapi, V. A. Novitsky, B. Brenner, M. Oliveira, D. Moisi, H. Moffat, I. Thior, M. Essex, and M. A. Wainberg. 2006. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen. Antimicrob. Agents Chemother. 50:2210-2213.
7. Eshleman, S. H., G. Becker-Pergola, M. Deseyve, L. A. Guay, M. Mracna, T. Fleming, S. Cunningham, P. Musoke, F. Mmiro, and J. B. Jackson. 2001. Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV Network for Prevention Trials 012 study). J. Infect. Dis. 184:914-917.
8. Gallant, J. E., S. Staszewski, A. L. Pozniak, E. DeJesus, J. M. Suleiman, M. D. Miller, D. F. Coakley, B. Lu, J. J. Toole, and A. K. Cheng. 2004. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292:191-201.
9. Garcia-Lerma, J. G., H. MacInnes, D. Bennett, P. Reid, S. Nidtha, H. Weinstock, J. E. Kaplan, and W. Heneine. 2003. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J. Virol. 77:5685-5693.
10. Gu, Z., H. Salomon, J. M. Cherrington, A. S. Mulato, M. S. Chen, R. Yarchoan, A. Foli, K. M. Sogocio, and M. A. Wainberg. 1995. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxycthyl)adenine. Antimicrob. Agents Chemother. 39:1888-1891.
11. Jemsek, J., P. Hutcherson, and E. Harper. 2004. Poor virologie responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif.
12. Osmanov, S., C. Pattou, N. Walker, B. Schwardlander, and J. Esparza. 2002. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J. Acquir. Immune Defic. Syndr. 29:184-190.
13. Parikh, U., D. Koontz, and N. Sluis-Cremer. 2004. K65R: a multinucleoside resistance mutation of increasing prevalence exhibits bi-directional phenotypic antagonism with TAM. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif.
14. Robbins, G. K., V. De Gruttola, R. W. Shafer, L. M. Smeaton, S. W. Snyder, C. Pettinelli, M. P. Dube, M. A. Fischl, R. B. Pollard, R. Delapenha, L. Gedeon, C. van der Horst, R. L. Murphy, M. I. Becker, R. T. D'Aquila, S. Vella, T. C. Merigan, M. S. Hirsch, and the AIDS Clinical Trials Group 384 Team. 2003. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N. Engl. J. Med. 349:2293-2303.
15. Roge, B. T., T. L. Katzenstein, N. Obel, H. Nielsen, O. Kirk, C. Pedersen, L. Mathiesen, J. Lundgren, and J. Gerstoft. 2003. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir. Ther. 8:173-182.
16. Salomon, H., M. A. Wainberg, B. Brenner, Y. Quan, D. Rouleau, P. Cote, R. LeBlanc, E. Lefebvre, B. Spira, C. Tsoukas, R. P. Sekaly, B. Conway, D. Mayers, J. P. Routy, et al. 2000. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS 14:F17-F23.
17. Snoeck, J., K. Van Laethem, P. Hermans, E. Van Wijngaerden, I. Derdelinckx, Y. Schrooten, D. A. van de Vijver, S. De Wit, N. Clumeck, and A. M. Vandamme. 2004. Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001. J. Acquir. Immune Defic. Syndr. 35:279-285.
18. Stone, C., M. Ait-Khaled, C. Craig, P. Griffin, and M. Tisdale. 2004. Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine. Antimicrob. Agents Chemother. 48:1413-1415.